Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (original) (raw)

2003, New England Journal of Medicine

Abstract

sparkles

AI

Preterm delivery before 37 weeks gestation significantly contributes to infant mortality in developed countries. Increasing rates of preterm delivery in the U.S. highlight the need for effective preventative measures. Progestational compounds have shown promise; this study investigates the efficacy of 17 Alpha-Hydroxyprogesterone Caproate (17P) in reducing recurrent preterm deliveries. Results indicate that treatment with 17P significantly lowers the risk of preterm delivery, suggesting it as a viable option in prophylactic care for women with a history of preterm births.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (28)

  1. and Human Development Maternal-Fetal Medicine Units Network are as follows: University of Alabama, Birmingham: A. Northen, D. Rouse; Brown University: H. Silver, J. Tillinghast; Case Western Reserve University: P. Catalano, C. Milluzzi; University of Chicago: P. Jones, M. Lindheimer; University of Cincinnati: N. Elder, T. Siddiqi; Columbia University: M. D'Alton, V. Pem- berton;
  2. George Washington University Biostatistics Center: A. Das, S. Leindecker; Magee Women's Hospital: M. Cotroneo, K. Lain; University of Miami: C. Alfonso, S. Beydoun; National Institute of Child Health and Human Development: D. McNellis, S. Pagliaro, A. Willoughby; University of North Carolina, Chapel Hill: K. Dorman, K. Moise; Northwestern University: G. Mallet, M. Socol; Ohio State University: F. Johnson, M. Landon; University of Tennessee: R. Ramsey; University of Texas at San Antonio: O. Langer, S. Nicholson; University of Texas at Houston: M. C. Day, L. Gilstrap; University of Texas Southwestern Medical Center: J. McCampbell, G. Wendel; MCP Hahnemann University: M. DiVito, J. Tolosa; University of Utah: M. Belfort, E. Taggart; Wake Forest University: E. Mueller-Heubach, M. Swain; Wayne State University: G. Norman, Y. Sorokin. references
  3. Paneth NS. The problem of low birth weight. Future Child 1995;5:19-34.
  4. Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 2001;15:Suppl 2:7-16.
  5. Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol 1993; 168:1223-30.
  6. LeVine L. Habitual abortion: a controlled clinical study of pregestational therapy. West J Surg Obstet Gynecol 1964;72:3036.
  7. Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17 a -hydroxy- progesterone caproate in the prevention of premature labor. N Engl J Med 1975;293: 675-80.
  8. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha- hydroxyprogesterone caproate. Am J Obstet Gynecol 1985;151:574-7.
  9. Hartikainen-Sorri A-L, Kauppila A, Tu- imala R. Inefficacy of 17 a hydroxyproges- terone caproate in the prevention of prema- turity in twin pregnancy. Obstet Gynecol 1980;56:692-5.
  10. Hauth JC, Gilstrap LC III, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxy- progesterone caproate on pregnancy out- come in an active-duty military population. Am J Obstet Gynecol 1983;146:187-90.
  11. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of random- ized control trials of progestational agents in pregnancy. Br J Obstet Gynecol 1989;96: 265-74.
  12. Keirse MJNC. Progesterone administra- tion in pregnancy may prevent preterm de- livery. Br J Obstet Gynaecol 1990;97:149- 54. 12. Iams JD, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. Am J Ob- stet Gynecol 1998;178:1035-40.
  13. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials. Control Clin Trials 1988;9:345-64. [Erratum, Control Clin Trials 1989;10:126a.]
  14. Iams JD, Newman RB, Thom EA, et al. Frequency of uterine contractions and the risk of spontaneous preterm delivery. N Engl J Med 2002;346:250-5.
  15. Lan KKG, DeMets DL. Discrete sequen- tial boundaries for clinical trials. Biometrika 1983;70:659-63.
  16. Goldenberg RL, Iams JD, Mercer BM, et al. The Preterm Prediction Study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. Am J Public Health 1998;88:233-8.
  17. Hauth JC, Andrews WW, Goldenberg RL. Infection-related risk factors predictive of spontaneous preterm labor and birth. Prenat Neonat Med 1998;3:86-90.
  18. Siiteri PK, Serón-Ferré M. Some new thoughts on the feto-placental unit and par- turition in primates. In: Novy MJ, Resko JA, eds. Fetal endocrinology. New York: Aca- demic Press, 1981:1-34.
  19. Garfield RE, Kannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglan- dins. Am J Physiol 1980;238:C81-C89.
  20. Challis JRG. Sharp increases in free cir- culating oestrogens immediately before par- turition in sheep. Nature 1971;229:208.
  21. Mitchell B, Cruickshank B, McLean D, Challis J. Local modulation of progesterone production in human fetal membranes. J Clin Endocrinol Metab 1982;55:1237-9.
  22. Frydman R, LeLaidier C, Baton-Saint- Mleux C, Hernandez H, Vial M, Bourget P. Labor induction in women at term with mife- pristone (RU 486): a double-blind, random- ized, placebo-controlled study. Obstet Gy- necol 1992;80:972-5.
  23. Sondergaard F, Ottesen B, Detlefsen G, et al. Traitement par la progesterone des menaces d'accouchment premature avec taux bas de progesterone plasmatique. Con- tracept Fertil Sexual 1985;13:1227-31.
  24. Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960; 79:172-6. 25. Goldzieher JW. Double-blind trial of a progestin in habitual abortion. JAMA 1964; 188:651-4.
  25. Swyer GIM, Daley D. Progesterone im- plantation in habitual abortion. Br Med J 1953;I:1073-7.
  26. Hobel CJ, Ross MG, Bemis RL, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994;170:54- 62. 28. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to re- duce the incidence of spontaneous preterm birth in women at increased risk: a random- ized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;1884:419-24.
  27. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980;22:251-70.
  28. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital ef- fects of first-trimester sex hormone expo- sure: a meta-analysis. Obstet Gynecol 1995;85:141-9.